Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer ...

Vilastobart in combination with atezolizumab continued to demonstrate a differentiated and generally well-tolerated safety profile. Treatment-related adverse events (AEs) were primarily Grade 1 or 2, ...
Seeking Alpha

Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its ...

-- Early progression-free survival (PFS) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ([95% CI, 0.34-1.67]; 62% censored) and 0.52 (48% relative risk reduction ...
Business Wire

Global Mobile Satellite Services (MSS) Market Analysis & Forecast 2016-2027 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Mobile Satellite Services (MSS) Market Analysis & Trends - Industry Forecast to 2027" report has been added to ResearchAndMarkets.com's offering. The Global Mobile ...

The Changing Economics Of Data Science: How AI Is Redefining Business Analytics

Thanks to AI, data science tasks that once demanded specialized skills can now be performed faster, more accurately and at a ...
ChannelBuzz.ca

SonicWall posts strong momentum from managed security services, cloud secure edge and zero trust network access solutions

Record bookings growth for SonicWall’s strategic solutions highlights SonicWall’s evolution into a full-scale cybersecurity leader and trusted managed services partner.